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Abstract: Background: Vitamin D deficiency is associated with sleep disorders and poor sleep quality.
Whether vitamin D supplementation (VDS) helps resolve these problems remains unclear. Objective:
To systematically review the effect of VDS on sleep quantity, quality, and disorders, and perform
a meta-analysis of available data. Methods: The reporting of this review followed the PRISMA
statement. VDS human interventions studies that reported on sleep quality, quantity, or disorders
were included. Medline, CINAHL, EMBASE, PsycInfo, the Cochrane Library, Clinicaltrials.gov,
and the ICTRP were searched, in addition to the references of the included articles and previous
relevant reviews, without language or time restrictions. Included studies were critically appraised,
findings were narratively synthesized, and a meta-analysis was conducted. Furthermore, the overall
certainty of the evidence was assessed. Results: A total of 19 studies were included (13 randomized
controlled trials (RCTs), 1 opportunistic addition to an RCT, 4 pre–post studies, and 1 pre–post study
analyzed as a case series); 3 RCTs were meta-analyses. The risk of bias was generally low. Pre–post
studies showed a significant improvement in sleep quality with VDS. Similarly, the results of the
meta-analysis revealed a statistically significant decrease in the Pittsburgh Sleep Quality Index with
VDS compared with placebo (mean difference, −2.33 (95% CI, −3.09, −1.57); p < 0.001; I2 = 0%), with
a moderate certainty of evidence. The results regarding the effect of VDS on sleep-related impairment,
difficulty, and disorders, as well as sleepiness and restless legs syndrome, were not unanimous.
Conclusions: VDS is promising in improving sleep quality; however, its effect on sleep quantity and
disorders needs to be further investigated.
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Inadequate sleep is a common public health problem of significant personal and societal burden [1]. Sleep disorders such as insomnia, obstructive sleep apnea (OSA), excessive
daytime sleepiness (EDS) and fatigue, sleep deprivation, and restless legs syndrome (RLS)
are increasingly being diagnosed in clinical practice [2]. It is estimated that 59% of young
adults suffer from a sleep disorder and do not get enough sleep [3] and only 36% of this population reports being free of sleep disturbances [4]. Inadequate sleep is an underappreciated
determinant of health [5,6] and can lead to short-term and long-term consequences. In the
short run, inadequate sleep may result in cognitive and motor performance impairments,
which can lead to decreased quality of life and reduced productivity [7,8]. In the longer
term, cumulative sleep deprivation can serve as a factor in the development and exacerbation of cardiovascular and metabolic diseases, cancer, diabetes mellitus, gastrointestinal
disorders, and mental illnesses [6,9]. Thus, the economic burden of inadequate sleep is
substantial, warranting urgent investment in health measures to address this issue [1].
Low vitamin D status is a prevalent condition that has been linked to a wide range
of adverse health outcomes [10,11]. Growing evidence has demonstrated that vitamin D
has a role in sleep regulation [12]. Specifically, vitamin D deficiency (VDD) can increase
risk of sleep disorders and is associated with sleep difficulties, shorter sleep duration, and
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nocturnal awakenings in children and adults [13–15]. The exact mechanisms by which
vitamin D regulates sleep are still far from being elucidated. Plausible theories include the
presence of vitamin D receptors on areas of the brainstem that are known to be pacemaker
cells playing an important role in sleep regulation [16,17], in addition to the potential role
of vitamin D in regulating melatonin, the “sleep hormone” [18].
Hence, it is plausible that vitamin D supplementation (VDS) might have a positive
effect on sleep disorders, including decreased sleep latency, improved sleep efficiency, and
longer sleep duration. Preventing and managing sleep disorders or correcting them by VDS
is of public health relevance, given the low cost of this intervention and its effectiveness
in other therapeutic areas. Given the lack of conclusive evidence in this regard, we aim to
systematically review the available literature on the effect of VDS on sleep quantity, quality,
and sleep disorders, and perform a meta-analysis of the available data.
2. Materials and Methods
2.1. Review Design
A predefined protocol registered at the OSF registries (DOI: 10.17605/OSF.IO/27BD3)
was followed to conduct this review. Ethical approval was not mandatory.
2.2. Criteria for Study Inclusion
Interventional studies, whether controlled or not, conducted on individuals not having
diseases or receiving medication known to influence vitamin D metabolism, such as chronic
kidney disease or liver disease, with or without sleep disturbances, including vitamin D
supplementation in any form, dose, or frequency as intervention, and reporting on the
prevalence or severity of sleep disorders [19], such as insomnia disorders, sleep-related
breathing disorders, central disorders of hypersomnolence, circadian rhythm sleep–wake
disorders, parasomnias, and sleep-related movement disorders, or sleep quantity or quality,
were included.
All studies extending supplementation for a minimum of 4 weeks were included in
this review to ensure adequate time for the intervention to produce an effect. In addition,
controlled studies involving a placebo, or a lower dose, or different form of vitamin D were
included. Finally, controlled studies including a co-intervention were included if both arms
of the study received the same co-intervention.
Eligible studies were those written in any language, irrespective of publication date
(i.e., no language or time limit).
Exclusion criteria included non-original studies (e.g., case reports, case series, editorials, and reviews) and studies conducted on participants with conditions (e.g., chronic
kidney disease) or on medications that might have an effect on vitamin D metabolism
(e.g., phenytoin, phenobarbital, carbamazepine, and rifampin). Finally, studies evaluating
the association between vitamin D status (hypo or hypervitaminosis D) and sleep were
not included.
2.3. Search Strategy
The author searched Medline via Ovid, the Cumulative Index to Nursing and Allied
Health Literature (CINAHL) via EBSCO, EMBASE via Ovid, APA PsycInfo via Ovid, the
Cochrane Library, Clinicaltrials.gov, and the International Clinical Trials Registry Platform
(ICTRP). Vitamin D supplementation and sleep were the key concepts followed in the
search strategy: for each concept, Medical Subject Headings (MeSH) and keywords were
recorded, whereby search terms included vitamin D, cholecalciferol, ergocalciferol or
calcidol, combined with sleep or insomnia. The author did not apply any language or
publication date restrictions to the search. The author also hand searched the reference lists
of included articles and previous relevant reviews for eligible studies. The electronic search
strategy was validated by a medical information specialist and the search strategy and
results for Medline, Embase, and the Chocrane Library are available in Supplementary S1.
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2.4. Study Selection
Studies meeting the inclusion criteria previously specified were identified by screening
titles and/or abstracts from electronic scientific databases via Endnote, version X6. Full
texts of potentially eligible studies were retrieved. Finally, records in the grey literature
search zone were further assessed for eligibility of inclusion.
2.5. Data Extraction
For all eligible studies, data related to the features of the study, population groups,
interventions given (type, form, and the dose of vitamin D in experimental groups, comparator, and duration), outcomes, and main findings were extracted and recorded in a data
extraction form. When reported as nmol/L, the author converted serum 25OHD to ng/mL
by dividing by a factor of 2.496. The author contacted the authors of some included studies
to obtain additional data, when they were not reported in the published studies.
2.6. Quality Assessment
The Cochrane criteria (sequence generation, allocation concealment, blinding of participants and outcome assessors, incomplete outcome data, and selective outcome reporting)
were used as the tool to assess the risk of bias of RCTs included in this review [20]. Furthermore, a modified version of the Cochrane Risk of Bias tool [21] (eligibility criteria,
measurement of exposure and outcome, control confounding, and follow-up) was used to
assess the risk of bias of non-randomized studies. Potential sources of bias for both RCTs
and non-randomized studies were graded as low, high, or unclear risk.
The Grading of Recommendations Assessment, Development, and Evaluation (GRADE)
criteria (risk of bias, inconsistency, indirectness, imprecision, and publication bias) were
used to assess the overall certainty of the evidence presented using GRADE Evidence
Profiles developed in the GRADEpro GDT software (www.gradepro.org; accessed on 8
November 2021).
2.7. Data Synthesis
A narrative composite of the study findings was provided when a meta-analysis
was not feasible. Furthermore, author-recorded features of the study, population group
characteristics, intervention provided, comparator, and the outcome were included in
this composite.
A meta-analysis was conducted when participants, treatments, and outcomes shared
similar characteristics to allow pooling. Standard meta-analyses comparing VDS with
placebo were performed using RevMan version 5.4 (The Cochrane Collaboration, The
Nordic Cochrane Centre). A random-effects model was used for the analysis of more
than two studies. The results were reported as the mean difference with 95% confidence
intervals. The I2 statistic was used to assess heterogeneity among different studies.
2.8. Quality of Reporting
The Preferred Reporting Items for Systematic reviews and Meta-Analyses literature
search extension (PRISMA-S) checklist and the PRISMA statement were followed for the
literature search component [22], and the reporting of this systematic review [23].
3. Results
3.1. Search Results
Details of the search process are presented in Figure 1. Out of the 19,051 screened
records, 19 studies were included in this systematic review. Out of these studies, thirteen
were RCTs [24–36], one was an opportunistic addition to an established randomized,
double-blind, placebo-controlled trial [37], four were pre–post studies [38–41], and one was
a self-controlled before–after trial, analyzed retrospectively as a case series [42].
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form of vitamin D was unclear in six trials [25,30,31,36,39,41]. Only Sharifan et al. [34]
assessed VDS in the form of fortified low-fat milk or low-fat yogurt. The duration of
supplementation ranged from 8 weeks [27,30,31,39,41] to a median of 5.3 years [32].
The average daily dose of VDS ranged from 1000 IU [29,39] to 7142.85 IU [30,35,42].
When reported, compliance with VDS was high in all studies. The majority of the studies were placebo controlled [24–28,30–32,35–37]. In two studies, the comparator was no
supplementation [29,39]; in one study, it was a lower dose of vitamin D [33]; in one study,
it was either low-fat milk or yogurt [34]. The most assessed outcome was sleep quality,
mainly using the Pittsburgh Sleep Quality Index (PSQI) [25,27,28,30,39,41,42].
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Table 1. Characteristics of included studies.

Study Population

Age
%Male

Control

Co-Intervention

Intervention
Duration
Daily Dose
Equivalent

Compliance

Vitamin D
Assessment

Ghaderi [25], Iran

Randomized,
double-blind,
placebo-controlled
trial

68 patients with maintenance
methadone treatment
referred to a clinic
(30 completed the trial:
I: n = 30; C:n= 30)

Age: Range: 25–70
Mean ± SD:
I: 40.1 ± 9.2
C: 42.5 ± 8.9
%Male: NR

Placebo, capsule

None

Vitamin D (unclear):
capsules
12 weeks
3571.42 IU

>90% in both groups

25(OH)D:
commercial
ELISA kit

Maheshwari [41],
NR

Pre–post study

40 patients diagnosed with
chronic low back pain

Age: Range: 25–65
%Male: 60%

Self

None

Vitamin D (unclear)
8 weeks
NR

NR

NR

Randomized,
double-blind,
placebo-controlled
trial

93 people with sleep
disorders (PSQI ≥ 5), but
without sleep disorders, not
using sleep medications,
recruited from a hospital
(89 completed the trial:
I:n= 44; C:n= 45)

Age: Range: 20–50
Mean ± SD:
I: 37.9 ± 9.50
C: 35.5± 10.00
%Male: I: 25.00; C:
22.22

Placebo, capsule

None

Vitamin D3: edible
pearls
8 weeks
3571.42 IU

I: 97.82%
C: 97.87%

25(OH) D:
Immunodiagnostic Systems
kit

Mason [28], USA

Randomized,
double-blind,
placebo-controlled
trial

218 overweight
(BMI ≥25 kg/m2)
postmenopausal women,
with serum 25(OH)D ≥10 to
<32 ng/mL undergoing
weight loss
I:n= 109; C:n= 109

Age: Range: 50–75
Mean ± SD:
59.6 ± 5.1
%Male: 0%

Placebo, gel
capsules

Lifestyle-based
weight-loss program
including a
reduced-calorie diet
(1200–2000 kcal/day,
<30% daily energy
intake from fat) and
225 min/week of
moderate-to-vigorous
aerobic activity

Vitamin D3, gel
capsules
12 months
2000 IU

I: 98%
C: 96%

25(OH)D:
DiaSorin
LIAISON
25-OH
Vitamin D
total assay

Mirzaei [30], Iran

Randomized,
double-blind,
placebo-controlled
trial

74 fibromyalgia syndrome
patients (according to the
American College of
Rheumatology criteria) with
25(OH)D < 30 ng/mL,
recruited from a
rheumatology center

Age: Range: 20–70
Mean ± SD:
Total: 41.6 ± 10.5
I: 42.1 ± 10.8
C: 41 ± 10.3
%Male: 0%

Trazodone 25 mg at
bedtime

Vitamin D (unclear)
8 weeks
7142.85 IU

NR

25(OH)D:
commercial
radioimmunoassay
kit

First Author,
Country

Study Design

Randomized, controlled trial
Sleep quality

Majid [27], Iran

Placebo
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Table 1. Cont.
First Author,
Country

Study Design

Study Population

Age
%Male

Randomized,
double-blind,
controlled trial

152 active-duty warfighters,
divided into no-treatment
group (C) (≥ 30 ng/mL) or
treatment group (I)
(<30 ng/mL) (131 completed
the trial)

Age: Mean ± SD:
I: 31.6 ± 8.2
C: 32.8 ± 10.5
%Male: 61.8%

Control

Co-Intervention

Intervention
Duration
Daily Dose
Equivalent

Compliance

Vitamin D
Assessment

None

Vitamin D3, gel
capsules
12 weeks
I1: 1000 IU
I2: 5000 IU

I1: 84.8%
I2: 87.9%
C: not required to
take pills

25(OH)D:
electrochemiluminescence

25(OH)D:
radioimmunoassay

25(OH)D:
Tandem mass
spectroscopy

Other outcomes

McCarthy [29],
Pacific Northwest

Okereke [32], USA

Rorie [33], USA

Randomized,
double-blind,
placebo-controlled
trial

Randomized,
double-blind,
controlled trial

Participants aged ≥50 years
in the VITAL-DEP (Vitamin
D and Omega-3
Trial-Depression Endpoint
Prevention) ancillary study
to VITAL, a randomized
clinical trial of cardiovascular
disease and cancer
prevention, without clinically
relevant depressive
symptoms at baseline
I:n= 9181; C:n= 9172

42 adult patients with
physician-diagnosed chronic
urticaria, recruited from
tertiary care clinics
I: n = 21; C: n = 21

Age: Mean ± SD:
Total: 67.5 ± 7.1
I: 67.5 ± 7.0
C: 67.4 ± 7.1
%Male: Total: 51%
I: 50.6%; C: 51.1%

Age:
I: Mean: 43.9; Range:
20–72
C: Mean: 43.1;
Range: 19–79
%Male: I: 14.2%;
C: 28.5%

No
supplementation

Placebo

None

Vitamin D3, pills
Median follow-up:
5.3 years
2000 IU

Adherence rates
(taking at least
two-thirds of pills as
assigned)
I:
Year 1: 94.8%
Year 2: 92.2%
Year 3: 91.5%
Year 4: 91.4%
Year 5: 90.6%
C:
Year 1: 94.6%
Year 2: 92.1%
Year 3: 91.0%
Year 4: 90.5%
Year 5: 89.8%

Low-dose
vitamin D3
(600 IU/d)

10 mg of cetirizine
twice daily and
increase to 4 times
daily as needed, 150
mg of ranitidine twice
daily, and 10 mg of
montelukast daily. In
addition to rescue
prednisone use for
intolerable or
uncontrolled
symptoms

Vitamin D3, pills (high
dose)
12 weeks
4000 IU

Excellent compliance
(1 subject in the low
vitamin D3 group
showed <80%
compliance)
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Table 1. Cont.

Study Design

Study Population

Age
%Male

Zhu [36], China

Randomized,
placebo-controlled
trial

158 patients with with
25(OH)D ≤ 75 nmol/L and
depression with tied anxiety
symptoms recruited through
advertisements, assessed by
the Mini-International
Neuropsychiatric Interview
to confirm the diagnosis of
major depressive disorders
(106 completed the trial:
I: n = 62; C: n = 44)

Age: Mean ± SD
I: 46.3 ± 9.7
C: 43.3 ± 13.7
%Male: I: 29%;
C: 22.7%

Kerley [26],
Ireland

Randomized,
double-blind,
placebo-controlled
trial

26 Caucasian adults with
OSA recruited from a sleep
clinic
(19 completed the trial: 15 on
CPAP therapy and 4 CPAP
naïve: I: n = 10; C:n= 9)

Age:
I: Range: 42–71
Mean ± SD: 56 ± 10
C: Range: 32–68
Mean ± SD: 52 ± 13
%Male: I: 89%; C:
60%

Randomized,
triple-blind,
placebo-controlled
trial

29 staff and students of a
university, aged 30–50 years,
with vitamin D deficiency
(<30 ng/mL), abdominal
obesity (waist circumference
(≥94 cm for men and ≥80 cm
for women), and symptoms
of insomnia (according to
validated Insomnia Severity
Index)
Milk: I: n = 8; C: n = 8
Yogurt: I: n = 7; C: n = 6

Age: Mean ± SD:
43.2 ± 6.59
Milk group: I: 39.5 ±
6.23; C: 44.5 ± 5.63
Yogurt group: I:
47.42 ± 6.8;
C: 41.5 ± 5.99
%Male:
Milk group: I: 20%;
C: 80%
Yogurt group: I:
57.1%; C: 42.8%

Randomized,
double-blind,
placebo-controlled
trial

35 patients with primary RLS
identified based on the RLS
diagnostic criteria of the
IRLSSG and recruited from
the Sleep Medicine and
Research Center
I: n = 17; C: n = 18

Age: Mean ± SD
I: 42.7 ± 4.7
C: 42.4 ± 5.5
%Male: I: 64.7%;
C: 72.2%

First Author,
Country

Sharifan [34], Iran

Wali [35], KSA

Sleep problems as adverse events of VDS

Co-Intervention

Intervention
Duration
Daily Dose
Equivalent

Compliance

Vitamin D
Assessment

Fish oil (current intake)

Vitamin D (unclear),
per os
6 months
1600 IU

NR

25(OH)D:
commercial
radioimmunoassay
kit

None

Vitamin D3: Capsule
15 weeks
4000 IU

93% in both
groups

Total 25(OH)D:
Architect
25(OH)D
CMIA

Simple low-fat
milk (200 mL/day)
Simple low-fat
yogurt (150 g/day)

None

I1: Vitamin
D3-fortified low-fat
milk containing
1500 IU Nan
I2: Vitamin
D3-fortified low-fat
yogurt
10 weeks
1500 IU

NR

25(OH)D:
commercial
ELISA kits

Placebo

None

Vitamin D3, per os
12 weeks
7142.85 IU

100%

NR

Control

Placebo

Placebo, capsule
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Table 1. Cont.
First Author,
Country

de Koning [24], the
Netherlands

Mohammadpour
[31], Iran

Age
%Male

Study Design

Study Population

Randomized,
double-blind,
placebo-controlled
trial

155 community-dwelling
older people, aged 60–80
years, recruited from the
general population or
through general practitioners,
with depressive symptoms,
and serum 25(OH)D between
15 and 50 nmol/L during
October–March or between
15 and 70 nmol/L during
April–September
I: n = 77; C: n = 78

Age: Median [IQR]
I: 67.8 [65.4–71.7] C:
67.3 [63.4–72.0]
%Male: I: 41.6%;
C: 43.6%

Randomized,
double-blind,
placebo-controlled
trial

62 children with ADHD
(based on DSM-IV criteria),
aged 5–12 years, referred
from psychiatric centers,
without psychiatric nor
neurologic comorbidities (54
completed the trial: I: n = 25;
C: n = 29)

Age: Mean ± SD:
Total: 7.87 ± 1.61
I: 7.70 ± 1.77
C: 8.03 ± 1.44
%Male: I: 71%;
C: 77.4%

Control

Intervention
Duration
Daily Dose
Equivalent

Compliance

Vitamin D
Assessment

Vitamin D3, tablet
12 months
1200 IU

87.10%

25(OH)D:
liquid chromatography
followed by
tandem mass
spectrometry

Methylphenidate

Vitamin D (unclear),
tablet
8 weeks
2000 IU

100%

25(OH)D3:
chemiluminescence

None

Vitamin D3, per os
18 months
6557.37 for 2 months,
then 3278.68 IU

NR

NR

Co-Intervention

Calcium tablet of
500 mg/day in case of
<2 dairy
consumptions/day
Placebo

Placebo

Participants were
allowed to take a
(multi)VDS with a
maximum of
400 IU/day in
addition to the study
tablets

Opportunistic addition to a randomized, controlled trial
Other outcomes

Slow [37], New
Zealand

Pre–post study
Sleep quality

Opportunistic
addition to an
established
randomized,
double-blind,
placebo-controlled
trial

322 healthy adults already
participating in the vitamin
D and acute respiratory
infections study (VIDARIS)
staff or students recruited
from a University.
(308 completed the trial:
I: n = 147; C: n = 146)

Age: Range: 18–67
Mean ± SD:
I: 47 ± 10
C: 48 ± 10
%Male: I: 25%;
C: 25%

Placebo
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Table 1. Cont.
First Author,
Country

Eshaghi [39], Iran

Study Design

Study Population

Age
%Male

Pre–post study

42 elderly women referred to
a sports counseling center,
with a PSQI > 11, without
sleep apnea, not smoking,
and not taking hypnotic
drugs (36 completed the trial)

Age: Range: 60–70
%Male: 0%

Control

No
supplementation
(habitual daily
activities)

Intervention
Duration
Daily Dose
Equivalent

Compliance

Vitamin D
Assessment

Vitamin D (unclear)
8 weeks
1000 IU

NR

NR

Vitamin D2
3 months
Vitamin D according to
deficiency level:
I1: Participants with
25(OH)D:
20–29 ng/mL: 5000 IU
I2: Participants with
25(OH)D < 20 ng/mL:
7142.86 IU

NR

25(OH)D:
radioimmunoassay
using
commercial
kits

None

Vitamin D3 (unclear)
6 months
NR

NR

NR

None

INS: Vitamin D3:
per os
DEF: Vitamin D2:
per os
12 weeks
INS: 1200 IU
DEF: 7142.85 IU

NR

25(OH)D:
liquid
chromatographymass
spectrometry
assay

Co-Intervention

Other outcomes

Guler [40], Turkey

Pre–post study

Cases: 60 patients with ASD
according to DSM V criteria,
aged between 4 and 10 years
Controls: 60 age- and
sex-matched apparently
healthy children

Arico [38], Italy

Pre–post study

5 patients with RLS recruited
from a sleep center

Age: Mean ± SD:
Cases: 7.10 ± 1.50
Controls: 6.93 ± 1.59
%Male: Cases: 73.3%;
Controls: 65%

Age: NR
%Male: 0%

Self

Pre–post study, analyzed retrospectively as a case series
Sleep quality

Huang [42], USA

Pre–post study,
analyzed
retrospectively as a
case series by
medical record
review

46 veterans with multiple
areas of chronic pain and low
serum 25(OH)D (<30 ng/mL)
at baseline recruited from a
major Veterans Affairs
Medical Center, divided into
vitamin D (1) INS: 25(OH)D:
20–29 ng/mL; and (2) DEF:
25(OH)D: <20 ng/mL
(28 completed the trial:
INS: n = 15; DEF: n = 13)

Age: Mean ± SD:
46.2 ± 10.8
%Male: 64.3%

Self

I: intervention; C: control; PSQI: Pittsburgh Sleep Quality Index; OSA: obstructive sleep apnea; NR: not reported; INS: insufficient; DEF: deficient; VDS: vitamin D supplementation;
25(OH)D: 25-hydroxyvitamin D; SD: Standard Deviation; IU: International Unit; CPAP: Continuous Positive Airways Pressure; CMIA: Chemiluminescent Microparticle Immunoassay;
ELISA: Enzyme-Linked Immunosorbent Assay; RLS: restless legs syndrome; IRLSSG: International Restless Legs Syndrome Study Group; DSM: Diagnostic and Statistical Manual of
Mental Disorders; ADHD: Attention Deficit Hyperactivity Disorder; IQR: Interquartile Range; ASD: Autism Spectrum Disorder.
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Table 2. Results of included studies.
Outcomes Evaluated and
Assessment

Baseline 25OHD Level

Endline 25OHD Level

Baseline Outcomes

Endline Outcomes

Conclusion

Ghaderi [25], Iran

Sleep quality: PSQI

I: 13.9 ± 4.5
C: 13.5 ± 4.5
(NS difference between I
and C)

I: 22.0 ± 7.5 (sig. increase)
C: 13.1 ± 5.9

I: 6.0 ± 2.3
C: 6.6 ± 2.2

I: 4.5 ± 2.2 (sig. decrease)
C: 6.4 ± 3.0

PSQI sig. decreased in VDS I group
compared with C group (−1.5 ± 2.2 vs.
−0.2 ± 2.3)

Maheshwari [41], NR

Sleep quality: PSQI

NR

NR

NR

t-test: 2.965; CI: 1.8312–6.8341; p =
0.004 (sig. differences before and
after VDS)

VDS improves sleep in patients with
chronic low back pain

I: 37.69 ± 12.25
C: 27.97 ± 7.46
(sig. increase in I, and sig.
difference between I and C)

PSQI (score) (NS difference
between I and C)
I: 9.45 ± 2.44
C: 10.51 ± 3.14
Sleep duration (hour) (sig. higher
in I compared with C)
I: 5.83 ± 1.15
C: 5.22 ± 1.54
Sleep latency (minute) (NS
difference between I and C)
I: 49.88 ± 38.99
C: 65.00 ± 47.54
Sleep efficiency (%) (NS
difference between I and C)
I: 82.58 ± 9.93
C: 78.20 ± 12.90
Sleep disturbances (score) (NS
difference between I and C)
I: 1.23 ± 0.47
C: 1.40 ± 0.78
Use of sleep medications (time
per week) (NS difference between
I and C)
I: 2.07 ± 1.92
C: 0.77 ± 1.02
Day time dysfunction (score) (NS
difference between I and C)
I: 1.57 ± 0.99
C: 1.17 ± 0.93
Subjective sleep quality (score)
(NS difference between I and C)
I: 1.68 ± 0.77
C: 1.57 ± 0.62

PSQI (score) (sig. lower in I
compared with C)
I: 6.75 ± 2.97 (sig. decrease)
C: 9.73 ± 3.04
Sleep duration (hour) (sig. higher
in I compared with C)
I: 6.50 ± 1.49
C: 5.21 ± 1.44
Sleep latency (minute) (sig. lower
in I compared with C)
I: 33.18 ± 27.91
C: 58.57 ± 36.81
Sleep efficiency (%) (NS
difference between I and C)
I: 86.97 ± 11.39 (sig. decrease)
C: 80.89 ± 11.46
Sleep disturbances (score) (NS
difference between I and C)
I: 1.14 ± 0.46 (NS)
C: 1.41 ± 0.65 (NS)
Use of sleep medications (time
per week) (NS difference between
I and C)
I: 1.07 ± 0.94 (sig. decrease)
C: 1.20 ± 0.99
Day time dysfunction (score) (NS
difference between I and C)
I: 0.70 ± 0.96 (sig. decrease)
C: 0.75 ± 0.98
Subjective sleep quality (score)
(sig. lower in I compared with C)
I: 1.18 ± 0.62 (sig. decrease)
C: 1.46 ± 0.58

Reduced PSQI (improved sleep score),
reduced sleep latency, increased sleep
duration, and subjective sleep quality
with VDS.
NS difference in sleep efficiency, sleep
disturbances, and use of sleep
medications

First Author, Country
Randomized, controlled trial
Sleep quality

Sleep quality: PSQI
Sleep duration
Sleep latency
Sleep efficiency: real sleep
duration from the whole
time passed in bed
Majid [27], Iran
Sleep disturbances
Use of sleep medications
Daytime dysfunction:
experiencing problems
resulted by sleeplessness
Subjective sleep quality

I: 25.00 ± 8.95
C: 27.60 ± 8.30
(NS difference between I
and C)
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First Author, Country

Mason [28], USA

Mirzaei [30], Iran

Outcomes Evaluated and
Assessment

Baseline 25OHD Level

Endline 25OHD Level

Baseline Outcomes

Endline Outcomes

Conclusion

Sleep quality: PSQI

NR

NR

NR

NR

NS change in overall sleep quality
between VDS I and C groups
A greater magnitude of change in serum
25(OH)D was associated with an
increased need to take medications to
sleep and overall worse sleep quality
Deterioration in total PSQI among
women who became vitamin D replete
(≥32 ng/mL) compared with those who
remained <32 ng/mL (despite VDS)
VDS of 2000 IU/d may result in overall
worse sleep quality for postmenopausal
women with low circulating vitamin D
undergoing weight loss

Sleep quality: PSQI

I: 11.4 ± 6.7
C: 13.4 ± 7.3

I: 33.5 ± 12.2 (sig. higher in I
compared with C)
C: 13.3 ± 7.2

I: 10 ± 3.3
C: 10.75 ± 4.4

I: 6.2 ± 2.2
C: 8.2 ± 3.7 (sig. lower in I
compared with C)

Considerable improvements were
observed in the PSQI score of the both
study groups; yet there was a sig. greater
decrease in mean PSQI score in the I
compared with C group

Sleep-related impairment:
Questions from the National
Institutes of Health
Patient-Reported Outcomes
Measurement Information
System

I1: 22.2 ± 5.0
I2: 22.9 ± 4.7
C: 37.8 ± 5.6

I1: 30.80 ± 10.0
I2: 40.15 ± 7.5 (sig. higher in
I2 compared with I1 and C)
C: 34.46 ± 9.9

I1: 53.0 ± 7.0
I2: 48.3 ± 9.5
C: 51.5 ± 7.0

I1: 49.5 ± 9.5
I2: 45.2 ± 8.4
C: 49.3 ± 8.2

Statistically significant improvements
seen across groups and over time

NR

NS differences in likelihood of sleep
problems in the I compared with C group
Adjusted differences in change in
likelihood of PHQ-8 item-level
symptoms, comparing vitamin D3 to
Placebo:
Sleep problems: Likelihood ratio: 95%
CI: 1.00 (0.89–1.12)
Analyses were from repeated measures
logistic regression models, with
follow-up time modeled as an indicator;
models were controlled for age, sex, and
n-3 fatty acid randomization group.
Results show likelihood ratios and 95%
confidence intervals (95% CIs), which
reflect differences in the change in
likelihood of burden from each PHQ-8
item-level symptom, comparing vitamin
D3 to placebo treatment group.
Differences reflect the average effect over
all follow-up times since baseline

Other outcomes

McCarthy [29], Pacific
Northwest

Okereke [32], USA

Sleep difficulty (sleep
problems) as specific
depressive feature
(item-level symptom) from
the 8 item Patient Health
Questionnaire depression
scale: Trouble falling or
staying asleep, or sleeping
too much

25(OH)D < 20 ng/mL
I: 11.0%
C: 12.3%
Mean ± SD
I: 31.2 ± 9.8
C: 31.1 ± 10.0

NR

NR
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Table 2. Cont.
First Author, Country

Outcomes Evaluated and
Assessment

Baseline 25OHD Level

Endline 25OHD Level

Baseline Outcomes

Endline Outcomes

Conclusion

Rorie [33], USA

Nights of hives and sleep
interference: from the
Urticaria Symptom Severity
scores

Mean(SE)
C: 37.1(3.4)
I: 28.8(2.2)

Mean(SE)
C: 35.8(2.3)
I: 56.0(3.9) (sig. higher in I
compared with C)

NR

NR

Beneficial trends for sleep quality and
towards decreased interference with
sleep were observed with high vitamin
D3

Zhu [36], China

Sleep disorder: NR

I: 15.66 ± 4.20
C: 16.86 ± 5.04
(NS difference between I
and C group)

NR

NR

NR

Between-group linear mixed-model
analysis showed sig. decrease in Sleep
disorder (β: −0.588; 95% CI:
−1.061,−0.115), that was rendered NS
after controlling for confounding
variables (β: −0.355; 95% CI:
−0.963,0.227)

Kerley [26], Ireland

Sleepiness: ESS

I: 13.38 ± 4.64
C: 16.58 ± 8.81
(NS difference between I
and C)

I: 40.38 ± 15.98 (sig. increase)
C: 17.22 ± 8.57

I: 11.00 ± 5.00
C: 10.00 ± 6.00
(NS difference between I and C)

I: 6.00 ± 2.00
C: 7.00 ± 5.00
(NS difference between I and C)

No difference in ESS between the VDS I
group and C group

Changes in sleepiness
symptoms: Insomnia
Severity Index

Milk
I: 15.03 ± 3.91
C: 14.9 ± 7.34 (NS
difference between I and C
group)
Yogurt
I: 15.82 ± 4.09
C: 16.72 ± 2.96 (NS
difference between I and C
group)

Milk:
I: 18.57 (sig. increase
compared with baseline)
C: 14.66
Yogurt:
I: 19.93 (sig. increase
compared with baseline)
C: 16.26 (SD not reported)

Milk:
I: 18.5 ± 3.33
C: 17.25 ± 2.34
Yogurt:
I: 13.28 ± 5.12
C: 13 ± 3.54

Milk
I: 13.62 ± 3.29 (sig. increase
compared with baseline)
C: 16.5 ± 4.02 (NS difference
compared with baseline)
Yogurt
I: 17.57 ± 13.28 (NS difference
compared with baseline)
C: 16.66 ± 1.36 (NS difference
compared with baseline)

Fortified low-fat milk containing 1500 IU
vitamin D3 can improve insomnia
symptoms

I: 17.06 ± 12.6
C: 22.95 ± 16.98
(NS difference between I
and C group)

I: 6.09 ± 15.38 (sig. higher in
I compared with C group)
C: 21.23 ± 13.74

Total
I: 14.60 ± 4.5
C: 16.11 ± 6.2
In DEF patients
I: 14.82 ± 5.2
C: 16.81 ± 6.3

Total:
I: 14.5 ± 08.2 (NS difference
compared with baseline)
C: 10.3 ± 11.1 (sig. decrease
compared with baseline)
In DEF patients
I: 13.8 ± 8.9 (NS difference
compared with baseline)
C: 7.8 ± 13.9 (sig. decrease
compared with baseline)

NS difference in RLS severity score with
VDS suggesting that VDS does not
improve RLS symptoms

median [IQR]
I: 18.42 [13.02–22.83]
C: 17.68 [14.42–22.13]
(significance NR)

mean ± SD
I: 34.05 ± 6.41
C: 17.22 ± 7.21
(sig. difference between I and
C)

NA (sleep problems as adverse
event of VDS)

I: n = 1
C: n = 5
(NS difference between I and C)

NS difference in sleep problems as
adverse effect of VDS in
community-dwelling people with
depressive symptoms

Sharifan [34], Iran

Wali [35], KSA

RLS severity: IRLSSG rating
scale

Sleep problems as adverse events of VDS

de Koning [24], the
Netherlands

Sleep problems as adverse
event: registered by
telephone or face-to-face
contact
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Table 2. Cont.
First Author, Country

Mohammadpour [31], Iran

Outcomes Evaluated and
Assessment

Sleep problems as adverse
events: questionnaire

Baseline 25OHD Level

Endline 25OHD Level

Baseline Outcomes

Endline Outcomes

Conclusion

mean ± SD
I: 15.792 ± 5.259 C: 12.979
± 5.804 (NS difference
between I and C)

mean ± SD: I: 34.63 ± 9.54
(sig. increase between
baseline and endline)
C: 11.22 ± 5.11 (NS
difference between baseline
and endline)
Sig. difference between I
and C

NA (sleep problems as adverse
event of VDS)

Rate
I: 4
C: 1
(NS difference between I and C)

NS difference in sleep problems as
adverse effect of VDS as adjunctive
therapy in children with ADHD

I: 29.24 ± 8.81
C: 28.44 ± 8.81

NR

NR

I: 79%
C: 70% (NS difference between I
and C)

VDS did not reduce the adverse impact
of earthquakes in healthy adults

NR

Mean ± SD
I: 12.55 ± 1.01
C: 12.55 ± 1.01

Mean ± SD I: 10.11 ± 1.26
(significant difference compared
with baseline)
C: 12.44 ± 0.88 (contradictory
evidence regarding C group
between written (NS difference)
and tabulated (sig.
difference) results)

Sleep quality sig. improved by 19.1%
with VDS

Cases:
25(OH)D < 10 ng/mL: 0%
25(OH)D: 10–30 ng/mL:
11.7%
25(OH)D > 30 ng/mL): 88.3%
mean ± SD: 37.27 ± 6.51
Controls:
25(OH)D < 10 ng/mL: 0%

CSHQ total score
Cases: <41: 21.7%; ≥41: 78.3%
Controls: <41: 66.7%; ≥41: 33.3%
mean ± SD total sleep time
(hours)
Cases: 8.10 ± 0.97
Controls: 9.24 ± 0.89
In DEF participants
Total score
Cases: 52.05 ± 8.24
Controls: 42.00 ± 4.78
Bedtime resistance
Cases: 11.24 ± 2.49
Controls: 7.38 ± 1.01
Sleep-onset delay
Cases: 2.32 ± 0.79
Controls: 1.86 ± 0.89
Sleep duration

CSHQ total score
Cases: <41: 28.3%; ≥41: 71.7%
Controls: <41: 86.7%; ≥41: 13.3%
mean ± SD total sleep time
(hours)
Cases: 8.58 ± 0.96
Controls: 9.38 ± 0.88
(sleep time sig. different between
Cases and Controls)
In DEF participants
Total score
Cases: 46.43 ± 8.04; sig
Controls: 37.56 ± 2.80; sig
Bedtime resistance
Cases: 10.17 ± 2.66; sig
Controls: 7.21 ± 0.75; NS
Sleep-onset delay
Cases: 1.82 ± 0.80; sig
Controls: 1.08 ± 0.36; sig

Opportunistic addition to a randomized, controlled trial
Other outcomes

Slow [37], New Zealand

Specific questionnaire about
disruptions in sleeping
patterns as a consequence of
the earthquake on the 22nd
February 2011

Pre–post study
Sleep quality

Eshaghi [39], Iran

Sleep quality: PSQI

NR

Other outcomes

Sleep habits and disorders:
short version of the CSHQ

Cases:
25(OH)D < 10 ng/mL:
23.3%
25(OH)D: 10–30 ng/mL:
45%
25(OH)D > 30 ng/mL:
31.7%
mean ± SD: 25.58 ± 10.31
Controls:
25(OH)D < 10 ng/mL:
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Table 2. Cont.
First Author, Country

Outcomes Evaluated and
Assessment

Baseline 25OHD Level

Guler [40], Turkey

with a higher score reflecting
more disturbed sleep
behavior

23.3%
25(OH)D: 10–30 ng/mL:
38.3%
25(OH)D > 30 ng/mL:
38.3%
mean ± SD: 25.35 ± 9.92
(NS difference between
Cases and Controls)
In DEF participants:
25(OH)D:
Cases: 19.68 ± 6.22
Controls: 19.21 ± 7.35

Arico [38], Italy

RLS severity: IRLS-RS

10.3

Endline 25OHD Level

Baseline Outcomes

Endline Outcomes

Conclusion

25(OH)D: 10–30 ng/mL: 6.7%
25(OH)D > 30 ng/mL: 93.3%
mean ± SD: 37.15 ± 6.78
(NS difference between
Cases and Controls)
In DEF participants:
25(OH)D:
Cases: 37.26 ± 7.34; sig
Controls: 39.13 ± 7.74; sig

Cases: 5.41 ± 0.92
Controls: 4.41 ± 0.98
Sleep anxiety
Cases: 7.73 ± 2.59
Controls: 4.41 ± 0.80
Night wakings
Cases: 5.59 ± 1.61
Controls: 4.11 ± 1.39
Parasomnias
Cases: 9.80 ± 2.52
Controls: 8.51 ± 1.76
Sleep-disordered breathing
Cases: 3.63 ± 0.73
Controls: 3.59 ± 0.90
Daytime sleepiness
Cases: 10.44 ± 1.84
Controls: 9.89 ± 1.85
Total sleep time
Cases: 8.16 ± 0.89
Controls: 9.11 ± 0.89

Sleep duration
Cases: 4.70 ± 0.95; sig
Controls: 4.18 ± 0.90; sig
Sleep anxiety
Cases: 6.78 ± 2.35; sig
Controls: 4.05 ± 0.4; sig
Night wakings
Cases: 4.24 ± 1.59; sig
Controls: 3.32 ± 0.62; sig
Parasomnias
Cases: 8.75 ± 1.84; sig
Controls: 7.16 ± 0.44; sig
Sleep-disordered breathing
Cases: 3.41 ± 059; sig
Controls: 3.40 ± 0.76; sig
Daytime sleepiness
Cases: 10.17 ± 1.93; NS
Controls: 9.21 ± 1.08; sig
Total sleep time
Cases: 8.63 ± 0.85; sig
Controls: 9.29 ± 0.89; sig

VDS may be beneficial in ASD patients
and healthy individuals with
sleep disturbances

30.4 (no information on
statistical significance)

19.8

8.6 (no information on statistical
significance)

VDS has a therapeutic effect in
decreasing RLS severity

Total: 26.00 ± 8.38 (sig.
increase)
INS: 29.60 ± 11.67
DEF: 24.00 ± 5.79

Global PSQI score
Total: 13.46 ± 4.92
INS: 12.27 ± 5.55
DEF: 14.85 ± 3.83
Sleep latency (min)
Total: 67.22 ± 56.13
INS: 41.61 ± 48.21
DEF: 94.81 ± 52.15
Sleep duration (h)
Total: 4.59 ± 1.84
INS: 5.33 ± 1.88
DEF: 3.73 ± 1.41
Sleep efficiency (%)
Total: 59.79 ± 25.31
INS: 66.97 ± 23.7
DEF: 52.61 ± 25.70

Global PSQI score
Total: 12.22 ± 4.61 (sig. decrease)
INS: 11.29 ± 4.66
DEF: 13.23 ± 4.51 (sig. decrease)
Sleep latency (min)
Total: 57.86 ± 44.03 (sig. decrease)
INS: 39.83 ± 39.05
DEF: 78.65 ± 41.33 (sig. decrease)
Sleep duration (h)
Total: 5.30 ± 1.57 (sig. decrease)
INS: 5.90 ± 1.55 (sig. decrease)
DEF: 4.62 ± 1.33 (sig. decrease)
Sleep efficiency (%)
Total: 66.62 ± 18.61 (sig. increase)
INS: 70.34 ± 17.76
DEF: 62.33 ± 19.34 (sig. increase)

Sig. improvement in overall sleep
quality, sleep latency, sleep duration, and
sleep efficiency in veterans with multiple
areas of chronic pain with VDS (after
controlling for potential confounders
improvement in sleep efficiency became
borderline significant)
The magnitudes of sleep improvement in
latency, duration, and efficiency were all
larger in the DEF subgroup; however,
the difference in improvements between
the subgroups was NS except for
sleep latency

Pre–post study, analyzed retrospectively as a case series
Sleep quality

Huang [42], USA

Sleep quality: PSQI
Sleep latency: #2 “how long
has it usually taken you to
fall asleep each night” of
the PSQI
Sleep duration: #4 “how
many hours of actual sleep
did you get at night” of
the PSQI
Sleep efficiency: #4 + #1
“what time have you usually
gone to bed at night” + #3
“what time have you usually
gotten up in the morning” of
the PSQI

Total: 18.57 ± 5.42
INS: 22.73 ± 1.83
DEF: 13.77 ± 3.94

I: intervention; C: control; PSQI: Pittsburgh Sleep Quality Index; NR: not reported; INS: insufficient; DEF: deficient; VDS: vitamin D supplementation; 25(OH)D: 25-hydroxyvitamin D;
SD: Standard Deviation; NS: Not Significant; sig. Significant; IU: International Unit; ESS: Epworth Sleepiness Scale; NR: not reported; RLS: restless legs syndrome; IRLSSG: International
Restless Legs Syndrome Study Group; CI: confidence interval; IRLS-RS: International Restless Legs Syndrome Rating Scale; ADHD: Attention Deficit Hyperactivity Disorder; IQR:
Interquartile Range; ASD: Autism Spectrum Disorder; CSHQ: Children’s Sleep Habits Questionnaire IRLS-RS: International Restless Legs Syndrome Rating Scale; IRLSSG: International
Restless Legs Syndrome Study Group; CSHQ: Children’s Sleep Habits Questionnaire; PHQ-8 Item: The 8 item Patient Health Questionnaire depression scale; NA: Not Applicable; SE:
Standard Error.
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The pre–post studies by Huang et al. [42], Eshaghi et al. [39], and Maheshwari et al.
[41] investigated the effect of VDS on sleep quality assessed by the PSQI. All three trials
showed
a significant
improvement in overall sleep quality with VDS. However, the three
3.4. Sleep
Quality
trials were
and
did not
contain
ampleetinformation
allowing pooling;
hence,
The heterogeneous
pre–post studies by
Huang
et al.
[42], Eshaghi
al. [39], and Maheshwari
et al. [41]
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a meta-analysis
their
impossible.
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Mirzaei et al.
[30]
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effect
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sleep quality
by the PSQI.
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results was
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provided
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four
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Ghaderi
et did
al. [25],
al. numerical
[27], Masonoutcomes,
et al. [28], and
ing, whereas the study by Mason et al. [28]
notMajid
reporteton
and Mirzaei et al. [30] explored the effect of VDS on sleep quality assessed by the PSQI.
therefore was not included in the meta-analysis. This study showed no significant change
Only three [25,27,30] provided information and had similar characteristics to allow pooling,
in whereas
overall sleep
quality
withetVDS
and
deterioration
in total outcomes,
PSQI among
women who
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by Mason
al. [28]
dida not
report on numerical
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repleted
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D
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weightDloss.
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postmenopausal
with low circulating
vitamin
D undergoing
loss. plot
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Sleepiness
Two RCTs assessed the effect of VDS on sleepiness using different tools [26,34]. The
study of Kerley et al. [26], which was conducted on patients with OSA, did not report any
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Sleepiness
Two RCTs assessed the effect of VDS on sleepiness using different tools [26,34]. The
study of Kerley et al. [26], which was conducted on patients with OSA, did not report any
difference in sleepiness between the group receiving VDS and those receiving placebo. In
contrast, the study by Sharifan et al. [34], which was conducted on patients with insomnia,
showed a beneficial effect of vitamin D3-fortified low-fat milk on insomnia symptoms
compared with unfortified milk. No effect was detected with vitamin D3-fortified low-fat
yogurt compared with unfortified one.
RLS
The pre–post study conducted by Arico et al. [38] found that long-term VDS (6 months)
decreased RLS severity in a small population (5 patients). In contrast, the RCT by Wali et al. [35]
found no effect of VDS on severity of RLS compared with placebo.
3.6. Sleep Problems as Adverse Events of VDS
Sleep problems as an adverse event of VDS were assessed in the two RCTs conducted
by Mohammadpour et al. [31], and de Koning et al. [24]. Both studies showed no significant difference in sleep problems with VDS versus placebo in children with ADHD or
community-dwelling people with depressive symptoms, respectively.
4. Discussion
This systematic review and meta-analysis investigated the effect of VDS on sleep
quantity and quality, and sleep disorders. VDD is an emerging risk factor for suboptimal
sleep and sleep disorders [12,15,43]. Such an association has been observed in several
healthy and ill populations including factory workers, older community-dwelling men,
hemodialysis patients, and pregnant women [12]. Specifically, through a meta-analysis of
observational studies involving 9397 participants, Gao et al. found that participants with
VDD had increased odds of sleep disorders and poor sleep quality by 1.5 fold, short sleep
duration by 1.75 fold, and sleepiness by 1.36 fold. They also provided evidence that serum
25(OH)D below 20 ng/mL could significantly heighten the odds of unhealthy sleep [15].
Similarly, through a meta-analysis of observational studies conducted on 1864 subjects with
sleep disorders and 1340 control participants, Yan et al. [43] found that the average serum
vitamin D concentration in the group with sleep disorders was 0.75 ng/mL lower than that
in the control group [43].
The association between VDS and sleep regulation is biologically plausible and worth
investigation given its clinical and public health relevance. Nevertheless, we found a limited
number of human interventional studies—especially RCTs—and most of the included
studies focused on sleep quality compared with other sleep-related outcomes. The evidence
from included studies was promising regarding the effectiveness of VDS on enhancing sleep
quality; nevertheless, studies investigating sleep quantity and sleep disorders were scarce,
heterogeneous in terms of included populations and methodologies, and their findings
were not unanimous, preventing generating a solid conclusion. Hence, our results suggest
that VDS is promising in improving sleep quality; however, its effect on sleep quantity and
disorders needs to be further investigated.
Although the exact physiological mechanisms between vitamin D and sleep regulation
have not yet been fully uncovered, several direct and indirect mechanisms have been
suggested [12]. One potential mechanism is the extensive presence of vitamin D receptors
in many parts of the brain, specifically areas that affect sleep [44]. Another theory involves
the expression enzymes involved in vitamin D activation and degradation (25-hydroxylase
and 1- hydroxylase and 24-CYP24A1) in areas in the brain known to be involved in sleep
regulation including the supraoptic and paraventricular nuclei within the hypothalamus
and the substantia nigra [44,45]. Another plausible theory considers the effect of sunlight.
It is well known that vitamin D levels are regulated by exposure to sunlight and since
sunlight also affects the circadian rhythm, it is highly plausible to assume that there
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is a link between those factors [46–49]. Furthermore, the production of melatonin—a
hormone involved in the regulation of circadian rhythms and sleep—is regulated by
vitamin D; thus, impaired vitamin D levels could decrease melatonin levels, potentially
leading to sleep disorders [50,51]. One final plausible mechanism is that vitamin D, as
an immunomodulatory molecule, plays a role in downregulating inflammatory markers
that are involved in sleep regulation such as tumor necrosis factor α (TNF-α), cytokines
and prostaglandin D2. In the case of VDD, such inflammatory markers would be raised,
negatively affecting sleep [52,53]. All of these factors may explain our findings regarding
the beneficial effect of VDS on sleep quality.
The only study involving patients with OSA was conducted by Kerley et al. [26]. VDD
is a common finding in OSA patients compared with non-apneic subjects, and vitamin D
levels were shown to be inversely correlated with the severity of OSA [54]. This association
is likely to be mediated by complex pathogenetic mechanisms, such as immune system
modulation, myopathy, and inflammation; nevertheless, these mechanisms are not fully
understood yet. Additionally, this relationship seems to be confounded by numerous
factors, such as obesity [54]. Kerley et al. [26] did not find a beneficial effect of VDS on
improving sleepiness in this patient population. This might be due to the small sample
of the trial and to the fact that 90% of the VDS group were stable on continuous positive
airways pressure, which may have diluted any potential benefit of VDS [26].
Our findings concerning the effectiveness of VDS on RLS were contradictory [35,38].
VDD may play a role in this movement disorder through its link with dopaminergic dysfunction. Nevertheless, to date, the causality between VDD and RLS is only hypothesized.
This null effect, despite the significant improvement in vitamin D levels in the intervention
group, suggests that VDS may not have a therapeutic effect in RLS, although it may contribute to the pathophysiology of the syndrome [35]. The authors of this study argue that
in RLS, vitamin D levels in the brain are more important than in the blood. Accordingly,
the improvement in serum levels with VDS may not have sufficiently affected vitamin D
levels in the brain [35].
It should be noted that vitamin D levels in response to supplementation depend
on three factors, dose, frequency and interval [55]; accordingly, our findings could be
interpreted in light of this fact. For example, the RCTs that found a beneficial effect
of VDS on sleep disorders were conducted over a short period of time, i.e., 10 weeks
in the study by McCarthy et al. [29], and 12 weeks in the studies by Rorie et al. [33]
and Sharifan et al. [34]. In contrast, RCTs reporting no significant improvement in sleep
disorders with VDS were those conducted over a long duration, i.e., 6 months in the study
by Zhu et al. [36], 18 months in the study by Slow et al. [37], and a median follow-up
duration of 5.3 years in the study by Okereke et al. [32]. This observation, although it could
be attributed to seasonality, raises queries on whether extended supplementation with
vitamin D may not always result in better outcomes.
Finally, human circadian rhythms—sleep and wakefulness cycles—are synchronized
by environmental signals, especially light and dark intervals through sunlight [48]. Although intentional sun exposure could hence be recommended to enhance sleep and
vitamin D levels, it remains highly challenging to titrate one’s exposure, besides the documented negative side effects of ultraviolet irradiation.
Strengths and Limitations
Our study has numerous strengths. First, we followed a systematic approach in our
search and analysis, using a highly sensitive search strategy, and followed recommended
reporting approaches for the review [23] as well as the search strategy [22]. Second, we
contacted the authors of some included studies to obtain additional data when they were
not reported in the published studies. Unfortunately, we did not receive feedback from all
authors. Finally, the risk of bias of the majority of included studies was low.
Nevertheless, the current analysis had some limitations. First, we were limited to
study level rather than individual-level data, which would have been more accurate than
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the overall mean change in sleep. Second, there were variabilities between included studies,
which complicates the comparisons as well as the interpretation of our results, especially in
the study populations, the outcomes assessed, and the assessment methods. Third, some
papers did not provide crucial information such as the form of vitamin D, the levels of
vitamin D at the end of the study, the daily dose equivalent, the assessment method of
vitamin D levels, nor compliance with VDS. Although we contacted respective authors,
we could not obtain the needed information in some instances. This would have enabled
us to better interpret our findings. Fourth, while we tried to make the literature search as
exhaustive as possible, pertinent studies might have been missed; a common limitation
to systematic reviews. Furthermore, we did not have access to some potentially eligible
studies for full-text screening. Fifth, given the small number of studies investigating the
effect of VDS on sleep disorders and their heterogeneity, we could not perform a metaanalysis of their findings and our conclusion remains limited to a qualitative synthesis.
Finally, repeat screening, selection of studies, data extraction, and quality assessment was
not possible.
5. Conclusions
In conclusion, the evidence presented in this review suggests a beneficial role of VDS
in enhancing sleep quality. These results remain to be interpreted with caution given the
limited number of included RTCs and their relatively small sample size. Nevertheless, the
positive effects of such supplementation could be considered in clinical practice, especially
in the context of beneficial skeletal [56] and pleiotropic extraskeletal effects [57,58] of
vitamin D, as well as the relatively limited cost of VDS. As we could not find enough
studies assessing the effect of VDS on sleep disorders, OSA, sleepiness, and RLS, this
remains to be explored in future adequately powered, high-quality RCTs.
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Egierska, D.; Pietruszka, P.; Burzyńska, P.; Chruścicka, I.; Buchta, J. Pleiotropic effects of vitamin D3. J. Educ. Health Sport 2021, 11,
143–155. [CrossRef]

